ADVERTISEMENT

Government Payers

Canada’s New Pharmacare Committee “Excludes” Industry

As mandated by the recent Pharmacare Act in Canada, a new committee will make recommendations on how Canada can provide universal drug coverage to it citizens.

Hospital Equipment Spending Gets A Boost In UK Budget

UK chancellor of the exchequer Rachel Reeves said her 2024 budget announcement would address the problem of ‘hospitals being without the equipment they need.’

Germany’s Hospital And Reimbursement Reform Battles Into The Final Straight

“Flying blind” into healthcare reform was among the feisty criticisms of Germany’s proposed law on hospital care improvement during the final parliamentary plenary on 17 October. SPD health minister Karl Lauterbach has stoutly defended his reform.

French Bill Calls For €1bn In Drug Price Cuts, Simplifies Payback Mechanism

The 2025 social security financing bill includes measures to reduce spending on reimbursed drug costs, change the way that industry paybacks are calculated, and tackle medicine shortages.

Medtechs Dig Deep For UK System Positives But Take Issue With MHRA Fees Hike

A new UK medtech survey sets out industry’s market access and regulatory concerns and makes clear where system users see the need for improvement. There are some grounds for optimism, but the MHRA’s planned rise in regulatory fees could undo some of the good work.

For Generic Manufactures, New Medicare Drug Pricing Demo Is a Dud

The proposed CMS innovation center's $2 drug list model will not address the barriers to newer generics getting on Part D formularies and plans may have little incentive to participate in the demo, an industry group said.

For Generic Manufactures, New Medicare Drug Pricing Demo Is a Dud

The proposed CMS innovation center's $2 drug list model will not address the barriers to newer generics getting on Part D formularies and plans may have little incentive to participate in the demo, an industry group said. 

England Plans New Model For Use Of Lilly’s Mounjaro In Weight Loss

NHS England says it is proposing a “realistic but challenging uptake trajectory” that will make “this clinically and cost-effective drug” available to as many patients as possible without overwhelming health care providers.

French Industry Calls For Reduction In Rebates, Proposes Savings Plan

The French pharma industry body Leem says that the scale of its contribution to health insurance cost savings is undermining the industry’s financial sustainability.

A Map View Of US Biosimilar Uptake

Texas comes out on top for biosimilar uptake, but how do the other US states compare? Geographical data can pinpoint which states are embracing biosimilars, and which have a way to go.